China (Mainland)
Cabergoline CAS NO.81409-90-7
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- Cabergoline
- Cabaser; Dostinex; FCE-21336
- 81409-90-7
Quick Details
- ProName: Cabergoline
- CasNo: 81409-90-7
- Molecular Formula: C26H37N5O2
- PackAge: 10mg;50mg;100mg
- ProductionCapacity: 50-100 Metric Ton/Day
- Purity: 98% min
- Storage: -20℃
- LimitNum: 0 Metric Ton
Superiority
Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors.
Target: D2 Receptors
Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. Rat studies show cabergoline has a direct inhibitory effect on pituitary lactotroph cells. Treatment with cabergoline was not associated with increased prevalence of cardiac valves regurgitation in patients with HyperPRL. Mean cumulative dose of cabergoline was lower in patients with HyperPRL than that reported to be deleterious for patients with Parkinson's disease: hence, longer follow-up is necessary, particularly in patients receiving weekly doses > 3 mg [1].
url：#
Details
Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors.
Target: D2 Receptors
Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. Rat studies show cabergoline has a direct inhibitory effect on pituitary lactotroph cells. Treatment with cabergoline was not associated with increased prevalence of cardiac valves regurgitation in patients with HyperPRL. Mean cumulative dose of cabergoline was lower in patients with HyperPRL than that reported to be deleterious for patients with Parkinson's disease: hence, longer follow-up is necessary, particularly in patients receiving weekly doses > 3 mg [1].
url：#
